January 24, 2022
Life Sciences
  • The FDA is weighing whether to limit the authorization of monoclonal antibody treatments from Eli Lilly & Co. and Regeneron Pharmaceuticals Inc., which haven’t proved effective against the Omicron variant. According to a person familiar with the process, last week senior Biden administration health officials called governors to urge them not to use the treatments. A decision could come as soon as this week. (Article here)